Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 1:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Esophagus Neoplasms Clear all
Completed Phase 2 Interventional Results available

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

NCT03365791
View directory record Official record
Conditions
Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma, Soft Tissue Sarcoma, Ovarian Adenocarcinoma, Advanced Well-differentiated Neuroendocrine Tumors, Diffuse Large B Cell Lymphoma
Interventions
PDR001, LAG525
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
San Francisco, California • Port Saint Lucie, Florida • Athens, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Jun 11, 2026, 1:38 AM EDT
Completed Phase 1 Interventional

A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab

NCT02013154
View directory record Official record
Conditions
Esophageal Neoplasms, Adenocarcinoma of the Gastroesophageal Junction, Gastroesophageal Cancer, Squamous Cell Carcinoma, Gastric Adenocarcinoma
Interventions
DKN-01 150 mg, Paclitaxel, Pembrolizumab, DKN-01 300 mg
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Jun 11, 2026, 1:38 AM EDT
Terminated Phase 2 Interventional Results available

Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy

NCT03223662
View directory record Official record
Conditions
Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Esophageal Neoplasms, Squamous Cell Carcinoma
Interventions
Chemoradiotherapy, Esophagectomy
Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Jun 11, 2026, 1:38 AM EDT
Completed No phase listed Observational

Dexmedetomidine and Hypoxic Pulmonary Vasoconstriction in Thoracic Surgical Procedures and One-Lung Ventilation

NCT00839605
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer, Chest Wall Disorders
Interventions
Dexmedetomidine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
19 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Jun 11, 2026, 1:38 AM EDT
Completed Phase 1 Interventional

Doxil Topotecan Doublet Cancer Study

NCT00252889
View directory record Official record
Conditions
Small Cell Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer
Interventions
Topotecan and pegylated doxorubicin
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Jan 26, 2009 · Synced Jun 11, 2026, 1:38 AM EDT
Recruiting No phase listed Observational

Retrospective Review of Esophageal Cancer at MSKCC

NCT05706558
View directory record Official record
Conditions
Esophageal Cancer, Esophagus Cancer
Interventions
Esophagectomy
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jun 11, 2026, 1:38 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

NCT02859415
View directory record Official record
Conditions
Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms, Neoplasms, Germ Cell and Embryonal
Interventions
Mithramycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Jun 11, 2026, 1:38 AM EDT
Completed No phase listed Observational Results available

Advanced MRI Sequences for Radiation Therapy Treatment Planning

NCT02340715
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 89 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Jun 11, 2026, 1:38 AM EDT
Terminated Phase 1 Interventional

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

NCT04060342
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma
Interventions
GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
Drug
Lead sponsor
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Jun 11, 2026, 1:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Central Obesity on the Esophageal Epithelial Barrier

NCT02776982
View directory record Official record
Conditions
Gastroesophageal Reflux, GERD
Interventions
Confocal endomicroscopy, Mucosal impedance, Research biopsies, Bravo ambulatory pH monitor
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Jun 11, 2026, 1:38 AM EDT
Recruiting No phase listed Observational

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

NCT00991094
View directory record Official record
Conditions
Breast Carcinoma, Esophageal Carcinoma, Genitourinary System Carcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Lung Carcinoma, Malignant Central Nervous System Neoplasm, Malignant Digestive System Neoplasm, Malignant Solid Neoplasm
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jun 11, 2026, 1:38 AM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery

NCT00539617
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Erlotinib, 5-fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Jun 11, 2026, 1:38 AM EDT
Withdrawn Phase 2 Interventional

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

NCT03220009
View directory record Official record
Conditions
Cervical Carcinoma, Esophageal Carcinoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Oral Cavity Mucosal Melanoma, Recurrent Melanoma, Stage II Vulvar Cancer AJCC v7, Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7, Stage IV Oral Cavity Cancer AJCC v6 and v7, Stage IV Vulvar Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Vaginal Carcinoma
Interventions
Conventional Surgery, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Patient Observation, Radiation Therapy
Procedure · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Jun 11, 2026, 1:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

NCT03490292
View directory record Official record
Conditions
Resectable Esophageal Cancer, GastroEsophageal Cancer
Interventions
Avelumab combined with Chemoradiation, Carboplatin, Paclitaxel, Radiation
Combination Product · Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Jun 11, 2026, 1:38 AM EDT
Active, not recruiting Phase 1 Interventional

Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer

NCT04046575
View directory record Official record
Conditions
Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus
Interventions
Intensity Modulated Radiation Therapy, Carboplatin, MD Anderson Symptom Inventory (MDASI)-Plus module, EuroQol (EQ-5D), SF-12, MOS Social Support Measure, CES-D, Blood for ctDNA (optional), Blood for SCCA, Paclitaxel
Radiation · Drug · Other + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jun 11, 2026, 1:38 AM EDT
Not yet recruiting Not applicable Interventional

Enhancing Screening Practices for BE

NCT07335445
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Screening Reminder
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 11, 2026, 1:38 AM EDT
Completed Not applicable Interventional Results available

Ablation of Intestinal Metaplasia Containing Dysplasia

NCT00282672
View directory record Official record
Conditions
Barrett Esophagus
Interventions
Ablation System plus anti-secretory medication, Sham procedure plus anti-secretory medication
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 80 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
19
States / cities
Scottsdale, Arizona • Tucson, Arizona • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jun 11, 2026, 1:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE)

NCT05524844
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Sample Collection, Endoscopy results, Dietary questionnaire
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Jun 11, 2026, 1:38 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

NCT01196390
View directory record Official record
Conditions
Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery, Trastuzumab
Drug · Other · Radiation + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
634
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 407 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 11, 2026, 1:38 AM EDT
Completed Phase 2 Interventional

Avastin and Taxotere for Esophagogastric Cancer

NCT00137813
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Docetaxel, Bevacizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Jun 11, 2026, 1:38 AM EDT
Recruiting Phase 1 Interventional

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

NCT07085091
View directory record Official record
Conditions
NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
ALX2004
Drug
Lead sponsor
ALX Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Tampa, Florida • Farmington Hills, Michigan • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 11, 2026, 1:38 AM EDT
Completed Phase 1 Interventional

Rapamycin With Grapefruit Juice for Advanced Malignancies

NCT00375245
View directory record Official record
Conditions
Tumors, Neoplasm Metastasis
Interventions
Rapamycin (sirolimus), Grapefruit Juice
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Jun 11, 2026, 1:38 AM EDT
Recruiting Not applicable Interventional

Pilot Study for OCT Guided In Vivo Laser Capture Microdissection for Assessing the Prognosis of Barrett's Esophagus

NCT03830801
View directory record Official record
Conditions
Barrett Esophagus
Interventions
IVLCM tethered capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jun 11, 2026, 1:38 AM EDT
Recruiting Not applicable Interventional

PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial

NCT05775939
View directory record Official record
Conditions
Lung Carcinoma, Esophageal Carcinoma
Interventions
Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Questionnaire Administration
Other · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 11, 2026, 1:38 AM EDT